BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29477471)

  • 1. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
    Hua H; Zhu Y; Song YH
    Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
    Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
    Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
    Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
    Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells.
    Yang J; Pi C; Wang G
    Biomed Pharmacother; 2018 Jul; 103():699-707. PubMed ID: 29680738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
    Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
    Zhang R; Lian Y; Xie K; Cai Y; Pan Y; Zhu Y
    Bioengineered; 2021 Dec; 12(2):9162-9173. PubMed ID: 34696683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
    Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
    Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ophiopogonin‑B targets PTP1B to inhibit the malignant progression of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK signaling pathways.
    Yuan F; Gao Q; Tang H; Shi J; Zhou Y
    Mol Med Rep; 2022 Apr; 25(4):. PubMed ID: 35169857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo.
    Hui F; Qin X; Zhang Q; Li R; Liu M; Ren T; Zhao M; Zhao Q
    Biomed Pharmacother; 2019 Jan; 109():2365-2374. PubMed ID: 30551496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local anesthetic bupivacaine inhibits proliferation and metastasis of hepatocellular carcinoma cells via suppressing PI3K/Akt and MAPK signaling.
    Wang L; Guo W; Guan H; Yan N; Cai X; Zhu L
    J Biochem Mol Toxicol; 2021 Oct; 35(10):e22871. PubMed ID: 34338398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
    Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
    Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS
    Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
    Zhang Z; Zhu J; Huang Y; Li W; Cheng H
    Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.